ONBREZ* BREEZHALER* is a 24-hour long-acting β2-agonist (LABA) approved for maintenance treatment of airflow
obstruction in patients with COPD.
DORVAL, QC, July 11, 2013 /CNW/ - New Brunswick patients suffering from
chronic obstructive pulmonary disease (COPD) now have access to ONBREZ*
BREEZHALER* (indacaterol maleate) 75 mcg with its listing in the New
Brunswick Prescription Drug Program (NBPDP) formulary. ONBREZ*
BREEZHALER* is available in pharmacies province wide.
ONBREZ* BREEZHALER* is a long-acting β2-agonist (LABA) indicated for long-term maintenance bronchodilator
treatment of airflow obstruction in patients with COPD, including
chronic bronchitis and emphysema. As an inhaled, steroid-free COPD
treatment, ONBREZ* BREEZHALER* is not indicated for the relief of acute
deterioration of COPD, nor to treat asthma1.
"We are pleased that New Brunswick recognized the therapeutic value of
ONBREZ* BREEZHALER*, leading to its inclusion on the list of
recommended drugs reimbursed by the New Brunswick Prescription Drug
Program. Other provinces are also providing access to this new
treatment for Canadians with COPD," said Dr. Riad Sherif B., President of Novartis Pharmaceuticals Canada
"This approval is welcome news for patients in New Brunswick, offering
them a new option for COPD therapy." added Barbara MacKinnon President and CEO of the New Brunswick Lung
COPD is a chronic, progressive respiratory condition characterized by
gradual airway obstruction, shortness of breath, cough and sputum
production. 2009-2010 estimates show that 4% of Canadians are affected.
Cigarette smoking is the principal cause, accounting for 80% of COPD
About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field,
is committed to the discovery, development and marketing of innovative
products to improve the well-being of all Canadians. In 2012, the
company invested close to $100 million in research and development in
Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600
people in Canada. For further information, please consult www.novartis.ca.
*ONBREZ and BREEZHALER are registered trademarks.
1 ONBREZ* BREEZHALER* Product Monograph, October 24, 2012.
2 PHAC. Fast facts about Chronic Obstructive Pulmonary Disease
(COPD) 2011. Available from: www.phac-aspc.gc.ca/cd-mc/publications/copd-mpoc/ff-rr-2011-eng.php. Accessed March 15, 2013.
SOURCE: Novartis Pharmaceuticals Canada Inc.
For further information:
Novartis - Media Relations
Director, Corporate Communications
Novartis Pharmaceuticals Canada Inc.